Sacubitril/valsartan protected dopaminergic neurons in a Parkinson's rat model by inhibiting neprilysin to boost natriuretic peptide levels, activating the neuroprotective WNT/β-catenin pathway.
SAC/VAL > VAL aloneThe neprilysin inhibitor component (sacubitril) provided additional neuroprotection beyond the angiotensin blocker alone
What the researchers found
SAC/VAL was more neuroprotective than VAL alone in PD rats, likely through neprilysin inhibition boosting natriuretic peptides that activate the WNT/β-catenin pathway, while reducing oxidative stress and neuroinflammation.
Why it matters
Drug repurposing an approved heart failure medication for Parkinson's would be much faster and cheaper than developing new drugs. The natriuretic peptide mechanism provides a novel neuroprotective pathway.
How the study worked
Rotenone-induced PD model in male Wistar rats, with oral SAC/VAL (40 mg/kg/day) or VAL (20 mg/kg/day) for 6 weeks, assessing behavior, dopaminergic injury, DA/TH/NP levels, WNT/β-catenin pathway, and oxidative/inflammatory markers.
What this study cannot tell us
Rat model; rotenone-induced PD doesn't fully replicate human PD. Cannot separate all effects of SAC from VAL. Dosing may not translate directly to humans. Short treatment duration.
How to read the evidence
Well-controlled preclinical study with SAC/VAL vs VAL comparison enabling attribution of effects to neprilysin inhibition. Strong rationale for clinical investigation.
When this study was published
Published in 2025.
The bigger picture
This reveals that natriuretic peptides have neuroprotective properties beyond cardiovascular function, and that neprilysin inhibition (by boosting these peptides) could be a novel therapeutic strategy for neurodegeneration.
Questions still open
- Should heart failure patients on SAC/VAL be monitored for reduced PD risk?
- Could natriuretic peptides be directly administered as neuroprotective agents?
- Would SAC/VAL show benefits in human PD patients in a clinical trial?
Common questions
How does a heart failure drug help Parkinson's?
Could patients already on this drug be getting brain protection?
Read the original research
The enhanced Wnt/β-catenin pathway upregulation by sacubitril/valsartan via neprilysin inhibition compared to valsartan in the rotenone induced Parkinson's disease rat model.
Neuropharmacology, 283, 110734
Citation
Elkhial, Rania Tarek; Awny, Magdy M; El-Sayed, Elsayed K; Nofal, Shahira. (2026). The enhanced Wnt/β-catenin pathway upregulation by sacubitril/valsartan via neprilysin inhibition compared to valsartan in the rotenone induced Parkinson's disease rat model.. Neuropharmacology, 283, 110734. https://doi.org/10.1016/j.neuropharm.2025.110734